S01 will provide cell-based and in vivo experimental platforms as well as histopathological expertise and PDAC patient cohorts, which will be extensively used and critically needed by investigators of the entire consortium. First, S01 will provide access to a well characterized, standardized, validated and quality-controlled primary low passaged murine PDAC cell line resource (>1.700 distinct cell lines) representing major PDAC subtypes, and a prospective human PDAC organoid (PDO) collection that will be continuously and systematically expanded and characterized over the next years. Second, together with S02 this service project will perform pharmacogenomic profiling of 350 PDAC cell lines with 430 anti-cancer drugs; thereby it covers a broad spectrum of targets and PDAC heterogeneity, with respect to genetics and drug response. These resources will be essential for all projects addressing PDAC heterogeneity, context-specific phenotypes and vulnerabilities of PDAC subtypes. In addition, the drug screening platform will help project leaders to rapidly test new hypotheses and therapeutic concepts, which can then be translated in preclinical in vivo models. Third, S01 will provide a platform for the distribution of genetically engineered murine PDAC models and CIRSPR/Cas9-based somatic pancreatic genome engineering of adult mice. The somatic CIRSPR/Cas9 approach will dramatically increase the speed and efficiency to engineer genetic gain- and loss-of-function alterations in mice and analyze their contribution to PDAC initiation, progression and treatment resistance. Corresponding to the PDOs, S01 will provide organoid-derived xenotransplantion (PDOX) models to allow validation of therapeutic concepts in humanized PDAC models in vivo. Fourth, core histophathologic analyses provided by S01 will facilitate standardized tumor phenotyping, biobanking and reverse-translation. Several clinically annotated pancreatic cancer cohorts (nearly 800 patient samples), as well as PDAC specimens of the prospective organoid cohort, will serve as a rich resource for cross-species analyses and pre-clinical validation.